MIM
SQZ

MetLife Investment Management’s SQZ Biotechnologies Company SQZ Stock Holding History

MetLife Investment Management’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,534
Closed -$137K – 2578
2021
Q3 		$137K Buy
+9,534
New +$129K ﹤0.01% 2290

Other funds holding SQZ

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's SQZ Position: Q4 2021 in Review

MetLife Investment Management sold out of SQZ Biotechnologies Company (SQZ) in Q4 2021, closing a stake of 9,534 shares — an estimated $137K sold.

MetLife Investment Management first reported a position in SQZ in Q3 2021 and held it in 1 quarter. The position peaked at $137K in Q3 2021. 50 funds tracked by Wall St. Rank hold SQZ as of Q4 2021.

  • MetLife Investment Management reported no remaining SQZ Biotechnologies Company position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 9,534 SQZ Biotechnologies Company shares in Q4 2021, an estimated $137K.
  • MetLife Investment Management first reported a position in SQZ Biotechnologies Company in Q3 2021 and held it in 1 quarter.
  • MetLife Investment Management's SQZ Biotechnologies Company position peaked at $137K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.